Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | METAP2 | P50579 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.47 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13128926 | 0.84 | IDO1 (0.57) | ALDH1A1TSHRMEN1KMT2ALMNA | |
| SCHEMBL13128923 | 0.83 | ALDH1A1 (0.51) | ALDH1A1APPTSHRMEN1KMT2A | |
| SCHEMBL7562043 | 0.79 | ALDH1A1 (1.00) | ALDH1A1TSHRGPR27CCR2MEN1 | |
| SCHEMBL28435446 | 0.77 | ALDH1A1 (0.65) | ALDH1A1TSHRMEN1KMT2AKEAP1 | |
| SCHEMBL2740946 | 0.74 | CRHBP (0.59) | ALDH1A1TSHRMEN1MAPK1KMT2A | |
| SCHEMBL4623054 | 0.73 | ALDH1A1 (0.75) | ALDH1A1TSHRMEN1KMT2AKEAP1 | |
| SCHEMBL4799566 | 0.72 | ALDH1A1 (0.63) | ALDH1A1TSHRGPR27MEN1MAPK1 | |
| SCHEMBL7574222 | 0.71 | APP (0.73) | ALDH1A1APPMETAP2CCR2KMT2A | |
| SCHEMBL13128980 | 0.70 | L3MBTL1 (0.50) | ALDH1A1METAP2MEN1MAPK1KMT2A | |
| SCHEMBL29561400 | 0.69 | ALDH1A1 (0.71) | ALDH1A1TSHRGPR27MEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249135-A1 | SULFONAMIDES AND THEIR USE AS A MEDICAMENT | THE GENETICS COMPANY, INC. (CH) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249135-A1 | SULFONAMIDES AND THEIR USE AS A MEDICAMENT | BCOR, CBR3, SULT1E1 | ALDH1A1 3484/4885APP 4878/4885METAP2 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.